Margetuximab Outperforms Trastuzumab in Advanced HER2-Positive Breast Cancer
Margetuximab appears to be more effective than trastuzumab, each with chemotherapy, in women with pretreated ERBB2 (formerly HER2)-positive advanced breast cancer, which remains largely incurable, according to initial results of the SOPHIA trial.